Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin [1] (multiple letters)

Journal of Hepatology

Volumn 42, Issue 2, 2005, Pages 275-276

  Rizzetto, Mario ^a   Zeuzem, Stefan ^b  

^a MOLINETTE HOSPITAL   (Italy)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; COMPARATIVE STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; VIROLOGY; VIRUS TYPING;

EID: 12444302328     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.10.028     Document Type: Letter

References (7)

1. S. Zeuzem R. Hultcrantz M. Bourliere T. Goeser P. Marcellin J. Sanchez-Tapias Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 J Hepatol 40 2004 993 999
2. S.J. Hadziyannis H. Sette Jr T.R. Morgan V. Balan M. Diago P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
3. M.W. Fried M.L. Shiffman K.R. Reddy C. Smith G. Marinos F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
4. A. Alberti Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed? J Hepatol 40 2004 1032 1035
5. EASL International Consensus Conference on hepatitis C. Paris, 26–27 February 1999. Consensus statement. J Hepatol 1999;31:3–8.
6. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10–12, 2002. Hepatology 2002;36:S3–20.
7. D.B. Strader T. Wright D.L. Thomas L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171